glp-1 and mash A New Phase in Therapeutics: Resmetirom (THR-β Agonist) Semaglutide (GLP-1 Receptor Agonist) Resmetirom and GLP-1 agonists for

While initial studies indicate it may offer superior weight loss benefits, the long-term safety data are still developing

Research Grant Support- Intercept, Galectin, BMS, Novo Nordisk, Viking, Pfizer

Published data from the Phase 3b STRIDE trial reported that Ozempic 1 mg via subcutaneous (SC) injection once weekly improved maximum walking distance by 13% compared to placebo after 52 weeks

Forma parte de las seales de saciedad que permiten mantener un equilibrio en la ingesta de energa, resume Inka Miambres, miembro del comit gestor del rea de Obesidad de la Sociedad Espaola de Endocrinologa y Nutricin (SEEN)